A nurse is caring for a client in a cardiac unit. The client presents with intermittent chest discomfort that varies in intensity and duration. The nurse conducts an assessment to gather pertinent clinical information.

Based on the clinical findings, which characteristics are consistent with unstable angina or stable angina.

Ruptured esophageal varices are a life-threatening complication of portal hypertension, commonly associated with advanced liver disease. Massive upper gastrointestinal bleeding can occur due to the rupture of dilated veins in the esophagus, leading to rapid hypovolemia, shock, and potential death. Immediate priorities focus on stabilizing circulation, maintaining airway protection, and restoring intravascular volume. Rapid fluid resuscitation is essential to support perfusion while definitive treatments such as endoscopic banding or vasoconstrictor therapy are initiated.

Rationale:
A. Initiating intravenous fluid replacement therapy is the priority intervention because it helps restore circulating blood volume lost from acute hemorrhage. Prompt fluid resuscitation supports tissue perfusion and prevents hypovolemic shock, which is a major risk in ruptured esophageal varices. This stabilizing measure is essential before or alongside definitive control of the bleeding source.

B. Monitoring vital signs every 12 hours is inappropriate in this emergency situation because it is too infrequent to detect rapid hemodynamic deterioration. Clients with active variceal bleeding require continuous or very frequent monitoring of blood pressure, heart rate, and oxygen saturation. Delayed assessment could result in missed signs of shock or ongoing hemorrhage.

C. Administering oral anticoagulants is contraindicated because it would worsen active bleeding. Anticoagulants inhibit clot formation and would significantly increase the risk of uncontrolled hemorrhage in ruptured esophageal varices. Management instead focuses on hemostasis and supportive care, not blood thinning.

D. Encouraging the client to eat solid foods is unsafe and inappropriate during active gastrointestinal bleeding. Oral intake increases the risk of aspiration and does not contribute to hemostasis or stabilization. The client should typically be kept NPO (nothing by mouth) until bleeding is controlled and the gastrointestinal tract is stabilized.

Multiple sclerosis (MS) is a chronic autoimmune demyelinating disorder of the central nervous system characterized by periods of relapse and remission. Disease-modifying therapies are used to reduce inflammatory activity, decrease relapse frequency, and slow long-term neurological deterioration. Interferon beta is one of the first-line treatments for relapsing forms of MS. It works by modulating the immune response to reduce autoimmune attack on myelin.

Rationale:
A. Interferon beta medications are indicated for acute relapses of multiple sclerosis is incorrect because these drugs are not used to treat acute exacerbations. Acute relapses are typically managed with high-dose corticosteroids to rapidly reduce inflammation. Interferon beta is a long-term disease-modifying therapy rather than an acute treatment.

B. Interferon beta medication may help to reduce the frequency of relapses and slow disease progression in multiple sclerosis is correct. It modulates immune system activity, reducing inflammatory attacks on myelin and decreasing the number and severity of relapses. Over time, this can also slow the accumulation of neurological disability associated with MS progression.

C. Interferon beta medications are contraindicated for clients who have multiple sclerosis is incorrect because these drugs are specifically approved for use in relapsing forms of MS. They are commonly prescribed as part of first-line disease-modifying therapy to manage the long-term course of the disease.

D. Interferon beta medications are only effective in managing symptoms but do not alter the disease course of multiple sclerosis is incorrect because these medications are disease-modifying rather than purely symptomatic. They reduce disease activity by decreasing immune-mediated damage to myelin, thereby influencing the progression of MS rather than only relieving symptoms.